Miss Shamyla Siddique

Miss Shamyla Siddique

Institute of Cancer and Genomic Sciences
Haematology Trials Team Leader

Contact details

Telephone
+44 (0) 121 371 4396
Fax
+44 (0) 121 371 4398
Email
s.siddique@bham.ac.uk
Address
Cancer Research UK Clinical Trials Unit (CRCTU)
College of Medical and Dental Sciences
University of Birmingham
Edgbaston
Birmingham
B15 2TT
UK

Shamyla Siddique is the Haematology Trials Team Leader at the at the Cancer Research UK Clinical Trials Unit (CRCTU) at the University of Birmingham.

Qualifications

  • MPhil in Evidence-based Pharmacotherapy 2005
  • BSc (Hons) Pharmaceutical Sciences, 2002

Biography

Shamyla Siddique graduated with a Pharmaceutical Sciences degree in 2002 and obtained her MPhil from Aston University in 2005. She joined the CRCTU as a Trial Coordinator in September 2005 coordinating a national, multicentre, phase II trial in Acute Myeloid Leukaemia (AML), designed to evaluate the combination of epigenetic therapies in patients with relapsed or refractory disease.

She subsequently coordinated a number of early phase multicenter trials in a variety of haematological malignancies and stem cell transplantation.

She was promoted to Senior Trial Coordinator in 2010 managing of portfolio of haematology trials for which the CRCTU was Sponsor. She has also worked closely with clinical teams at the Queen Elizabeth Hospital and has run trials on behalf on a site and Sponsor. In 2014, she was appointed to Haematology Trials Team Leader and currently leads Leukaemia and Lymphoma Research’s Trials Acceleration Programme (‘TAP’) with the CRCTU.

Research

Shamyla Siddique has contributed to the design, set-up and/or management of the following trials:

  • VAL/Aza (Acute Myeloid Leukaemia)
  • MiniAlloGlivec (Chronic Myeloid Leukaemia)
  • TRICE (Chronic Myeloid Leukaemia)
  • RICAZA (Acute Myeloid Leukaemia, Allogeneic Stem Cell Transplantation)
  • LenaRIC (Multiple myeloma, Allogeneic Stem Cell Transplantation)
  • HA-1 (Phase I, healthy volunteer vaccination trial)
  • RAvVA (Acute Myeloid Leukaemia)
  • ROMAZA (Acute Myeloid Leukaemia)
  • FIGARO (Acute Myeloid Leukaemia, Allogeneic Stem Cell Transplantation)
  • VIOLA (Acute Myeloid Leukaemia, Allogeneic Stem Cell Transplantation)
  • AZTEC (Graft versus Host Disease)
  • BUBBLE (Multiple Myeloma)

Other activities

  • Member of the National Cancer Research Institute Haemato-Oncology Clinical Studies Group since 2014

Publications

Craddock, C., Quek, L., Goardon, N., Freeman, S., Siddique, S., Raghavan, M., Aztberger, A., Schuh, A., Grimwade, D., Ivey, A., Virgo, P., Hills, R., McSkeane, T., Arrazi, J., Knapper, S., Brookes, C., Davies, B., Price, A., Wall, K., Griffiths, M., Cavenagh, J., Majeti, R., Weissman, I., Burnett, A., Vyas, P (2012). Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia. Leukemia; Nov 6.

Goodyear, O., Dennis, M., Jilani, N., Loke, J., Siddique, S., Ryan, G., Nunnick, J., Khanum, R., Raghavan, M., Cook, M., Snowden, J., Griffiths, M., Russell, NH., Yin, J., Crawley, C., Cook, G., Vyas, P., Moss, PAH., Malladi, R., Craddock, CF (2012). "Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia." Blood.

Goodyear, O., Agathanggelou A., Novitzky-Basso, I. Siddique, S,. McSkeane, T.Ryan, G.Vyas, P.Cavenagh, J.Stankovic, T.Moss, P.Craddock, C.(2010). "Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia." Blood 116(11): 1908-18.

Olavarria, E., S. Siddique, et al. (2007). "Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia." Blood 110(13): 4614-7.